Patents by Inventor Mark D. Wittman

Mark D. Wittman has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20020016356
    Abstract: The present invention concerns novel 7-deoxy taxane derivatives, their use as antitumor agents, and pharmaceutical formulations.
    Type: Application
    Filed: March 8, 2001
    Publication date: February 7, 2002
    Inventors: John F. Kadow, Wendy S. Schwartz, Paul M. Scola, Qiufen May Xue, Mark D. Wittman, Mu-Jen Wu
  • Publication number: 20010023255
    Abstract: The present invention concerns antitumor compounds. More particularly, the invention provides novel taxane derivatives, pharmaceutical compositions thereof, and their use as antitumor agents.
    Type: Application
    Filed: June 6, 1997
    Publication date: September 20, 2001
    Inventors: JERZY GOLIK, DOLATRAI VYAS, JOHN J. WRIGHT, HENRY WONG, JOHN F. KADOW, JOHN K. THOTTATHIL, WEN-SEN LI, MURRAY A. KAPLAN, ROBERT K. PERRONE, MARK D. WITTMAN
  • Patent number: 6201140
    Abstract: The present invention concerns novel 7-ethers of taxane derivatives, their use as antitumor agents and pharmaceutical compositions containing the novel compounds.
    Type: Grant
    Filed: July 28, 1994
    Date of Patent: March 13, 2001
    Assignee: Bristol-Myers Squibb Company
    Inventors: Henry Wong, Mark D. Wittman
  • Patent number: 5977386
    Abstract: The present invention concerns novel paclitaxel derivatives, their use as antitumor agents, and pharmaceutical formulations.
    Type: Grant
    Filed: November 26, 1997
    Date of Patent: November 2, 1999
    Assignee: Bristol-Myers Squibb Company
    Inventors: Andrew J. Staab, John F. Kadow, Dolatrai M. Vyas, Mark D. Wittman, Harold A. Mastalerz
  • Patent number: 5912264
    Abstract: The present invention concerns novel taxane derivatives, their use as antitumor agents, and pharmaceutical formulations.
    Type: Grant
    Filed: February 2, 1998
    Date of Patent: June 15, 1999
    Assignee: Bristol-Myers Squibb Company
    Inventors: Mark D. Wittman, John F. Kadow
  • Patent number: 5773461
    Abstract: The present invention concerns novel paclitaxel derivatives, their use as antitumor agents, and pharmaceutical formulations.
    Type: Grant
    Filed: June 4, 1997
    Date of Patent: June 30, 1998
    Assignees: Bristol-Myers Squibb Company, Virginia Tech Intellectual Properties, Inc.
    Inventors: Mark D. Wittman, Thomas J. Altstadt, John F. Kadow, David G. I. Kingston, Xian Liang
  • Patent number: 5646176
    Abstract: The present invention concerns antitumor compounds. More particularly, the invention provides novel taxane derivatives, pharmaceutical compositions thereof, and their use as antitumor agents.
    Type: Grant
    Filed: May 19, 1995
    Date of Patent: July 8, 1997
    Assignee: Bristol-Myers Squibb Company
    Inventors: Jerzy Golik, Dolatrai Vyas, John J. Wright, Henry Wong, John F. Kadow, John K. Thottathil, Wen-Sen Li, Murray A. Kaplan, Robert K. Perrone, Mark D. Wittman
  • Patent number: 5489589
    Abstract: The present invention concerns water-soluble amino acid derivatives of paclitaxel, their use as antitumor agents, and pharmaceutical compositions containg the compounds.
    Type: Grant
    Filed: December 7, 1994
    Date of Patent: February 6, 1996
    Assignee: Bristol-Myers Squibb Company
    Inventors: Mark D. Wittman, John F. Kadow
  • Patent number: 5478854
    Abstract: R.sup.g is C.sub.1-6 alkyl, C.sub.2-6 alkenyl, C.sub.2-6 alkynyl, C.sub.3-6 cycloalkyl, or a radical of the formula --W--R.sup.x in which W is a bond, C.sub.2-6 alkenediyl, or --(CH.sub.2).sub.t --, in which t is one to six; and R.sup.x is naphthyl, phenyl, or heteroaryl, and furthermore R.sup.x can be optionally substituted with one to three same or different C.sub.1-6 alkyl, C.sub.1-6 alkoxy, halogen or --CF.sub.3 groups;R.sup.2 is --OCOR, H, OH, --OR, --OSO.sub.2 R, --OCONR.sup.o R, --OCONHR, --OCOO(CH.sub.2).sub.t R, or --OCOOR; andR and R.sup.o are independently C.sub.1-6 alkyl, C.sub.2-6 alkenyl, C.sub.3-6 cycloalkyl, C.sub.2-6 alkynyl, or phenyl, optionally substituted with one to three same or different C.sub.1-6 alkyl, C.sub.1-6 alkoxy, halogen or --CF.sub.3 groups.Further provided by this invention are pharmaceutical formulations and intermediates for the the preparation of deoxy taxols of formula I. A method of treating mammalian tumors using a compound of formula I is also provided.
    Type: Grant
    Filed: March 10, 1994
    Date of Patent: December 26, 1995
    Assignee: Bristol-Myers Squibb Company
    Inventors: Vittorio Farina, Shu-Hui Chen, David Langley, Mark D. Wittman, Joydeep Kant, Dolatrai M. Vyas
  • Patent number: 5412082
    Abstract: Oxidation of primary amines to primary hydroxylamines using a dialkyl dioxirane is described. This new method is utilized to prepare aliphatic non-axial hydroxylamines from corresponding primary amino-substituted sugar derivatives and hydroxylamino acid derivatives.
    Type: Grant
    Filed: August 31, 1993
    Date of Patent: May 2, 1995
    Assignee: Yale University
    Inventors: Mark D. Wittman, Samuel J. Danishefsky, Randall L. Halcomb
  • Patent number: 5395849
    Abstract: The present invention provides novel antitumor agents which are hybrid molecules consisting of a cyclic enediyne unit attached to a DNA-binding unit via a linker unit, and having the general formula (I)D--(OCH.sub.2).sub.m --O--(CH.sub.2).sub.n --Ar--Y--CONH--B(I)wherein D is a cyclic enediyne; B is a residue capable of binding to the minor groove of DNA; n is 0 and m is 1, is or n is 1 and m is 0 or 1; Ar is an aromatic residue selected from the group consisting of phenyl, naphthyl, pyridyl, quinolinyl and indolyl; and Y is a direct bond, --CH.sub.2 -- or --CH.dbd.CH--; or a pharmaceutically acceptable salt thereof.
    Type: Grant
    Filed: October 5, 1993
    Date of Patent: March 7, 1995
    Assignee: Bristol-Myers Squibb Company
    Inventors: Mark D. Wittman, David Langley, John F. Kadow
  • Patent number: 5318989
    Abstract: The present invention relates to a novel and efficient process for the preparation of 8-hydroxybicyclo[7.3.1]tridec-4-ene-2,6-diyne ring system which is part of the aglycone of esperemicin and to novel cytotoxic antitumor agents having said bicyclic ring system. The present invention also provides a method for treating mammalian malignant tumors by administering to an animal in need of such treatment an antitumor effective amount of a compound of the present invention.
    Type: Grant
    Filed: December 18, 1992
    Date of Patent: June 7, 1994
    Assignee: Bristol-Myers Squibb Company
    Inventors: John F. Kadow, Mark D. Wittman
  • Patent number: 5278301
    Abstract: Axial anomeric sulfoxides generated via thiophenol Ferrier rearrangement of glucal and galactal derivatives are used to synthesize glycals of the gulal and allal series. An application of the method led to the synthesis of the esperamicin thiosugar.
    Type: Grant
    Filed: April 13, 1992
    Date of Patent: January 11, 1994
    Assignee: Yale University
    Inventors: Randall L. Halcomb, Samuel J. Danishefsky, Mark D. Wittman
  • Patent number: 5198560
    Abstract: The present invention relates to a novel and efficient process for the preparation of 8-hydroxybicyclo[7.3.1]tridec-4-ene-2,6-diyne ring system which is part of the aglycone of esperemicin and to novel cytotoxic antitumor agents having said bicyclic ring system. The present invention also provides a method for treating mammalian malignant tumors by administering to an animal in need of such treatment an antitumor effective amount of a compound of the present invention.
    Type: Grant
    Filed: October 25, 1991
    Date of Patent: March 30, 1993
    Assignee: Bristol-Myers Squibb Company
    Inventors: John F. Kadow, Mark D. Wittman
  • Patent number: 5104982
    Abstract: Axial anomeric sulfoxides generated via thiophenol Ferrier rearrangement of glucal and galactal derivatives are used to synthesize glycals of the gulal and allal series. An application of the method led to the synthesis of the esperamicin thiosugar.
    Type: Grant
    Filed: March 23, 1990
    Date of Patent: April 14, 1992
    Assignee: Yale University
    Inventors: Randall L. Halcomb, Samuel J. Danishefsky, Mark D. Wittman